> The FDA has agreed to give priority review for Revlimid as a treatment for cancer of the plasma cells found in bone marrow. Report

> The lead-poisoning drug Endrate has been linked to the death of two children. Report

> A hedge fund that holds nine percent of Chiron's stock says it will vote against a planned buyout by Novartis. Report

> The FDA has broadened the indication for Medicis Vanos, a Class I corticosteroid launched in April 2005 and originally indicated for the treatment of plaque-type psoriasis. Report

> A study involving mice shows that an experimental compound stopped both forms of brain lesions found in patients suffering from Alzheimer's. Report

> Roche has received its first product patent in India. Report

> Shire has sued Teva for alleged patent infringement involving Adderall XR. Report

> Research indicates that a new vaccine may cut the rate of inner ear infections. Report

> Takeda Pharmaceutical announced it received the exclusive right to use LG474, a substance discovered through its collaboration with Lexicon Genetics in the US. Release

> India's Amabalal Sarabhai Enterprises has closed its manufacturing operations.    Report

And Finally… Amgen CEO Kevin Sharer says that biosimilars will first appear in Europe and later gain approval in the U.S. But he says the market for biosimilars will develop in a dramatically different fashion than generic alternatives for pharma's compounds. Article